What ResMed's 8-K filings say: 4 filings, latest Sep 1, 2026
ResMed filed its latest 8-K with the SEC on Sep 1, 2026. It discusses divestiture, restructuring and restructuring charge.
Public (RMD)Medical Equipment Manufacturing5,001 to 10,000 employeesresmed.comLinkedIn
- Filed
- Sep 1, 2026
- Filings
- 4
- Signals
- 13
8-K · latest 8
What ResMed's 8-K filings say
- SEC EDGAR
8-K
Filed · 3 signals
ResMed divests MatrixCare business to fund $450M accelerated share repurchase.
The sale of the MatrixCare business indicates a strategic refocus on core operations and provides significant capital.
$450M
Amount of accelerated share repurchase funded by the sale of the MatrixCare business.
Citibank
- SEC EDGAR
8-K
Filed · 3 signals
The company appointed Carol Burt as the new Lead Director and replaced its long-time auditor KPMG with PwC following a competitive review.
KPMG LLPPricewaterhouseCoopers LLP
The retirement of director Ronald Taylor and appointment of Carol Burt as the new Lead Director signals a shift in board leadership and governance.
KPMG LLPPricewaterhouseCoopers LLP
ResMed replaces auditor KPMG with PwC following a competitive review process
This change in a critical external partner for financial oversight will require significant effort from finance and accounting teams to onboard the new firm.
KPMG LLPPricewaterhouseCoopers LLP
- SEC EDGAR
8-K
Filed · 3 signals
ResMed divests MatrixCare business for $490M, creating operational complexity and stranded costs.
The sale to Frazier Healthcare Partners necessitates Transition Services Agreements (TSAs) for systems and processes.
$490M
all-cash transaction to sell its MatrixCare business
ResMed divesting its MatrixCare business unit to Frazier Healthcare Partners for $490M.
This all-cash transaction will create significant operational complexity as ResMed must separate MatrixCare's systems, processes, and tools.
$490M
all-cash transaction for the sale of the MatrixCare business
Frazier Healthcare Partners
- SEC EDGAR
8-K
Filed · 4 signals
ResMed appoints new CFO Aaron Bloomer, effective May 4, 2026, replacing retiring Brett Sandercock.
$3.3M
New CFO sign-on long-term performance equity grant
80%
New CFO annual short-term cash incentive bonus target as a percentage of base salary
New CFO Aaron Bloomer also appointed as Principal Accounting Officer at ResMed.
With a new executive now leading the accounting function, a review of accounting systems, internal controls, and compliance processes is highly likely.
Showing 8 of 13 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track ResMed with the Signal API
One POST /v1/companies/enrich call with resmed.com returns ResMed 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"resmed.com","signal_types":["sec-8k"],"limit":20}'Same industry
8-K at related companies
Questions about ResMed 8-K
When did ResMed file its latest 8-K?
What did ResMed disclose in its latest 8-K?
Where can I read ResMed's 8-K filing?
Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .